BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » Page 67

Pricing Of Approved Cell Therapy Products

By 2 Comments

Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T therapy in the United States. Novartis announced that its genetically modified autologous (“self-derived”) immunocellular therapy, Kymriah, will cost $475,000 per treatment course. Shortly thereafter, Kite Pharma announced the approval of its CAR-T therapy, Yescarta, in the U.S. with a list price of $373,000. While these prices are expensive, they are far from trendsetting.

Cell Therapy Pricing and Products

In this article:

[Read more…]

StemSight Bolsters Leadership Team and Adds Extensive Experience in Cell Therapy Commercialization with Key Hire

By Leave a Comment

In the field of groundbreaking regenerative medicine, StemSight’s aim to cure blindness takes a major leap forward with the strategic appointment of Dr Ross Macdonald as Chief Commercial Officer. 

Tampere, Finland, 21.11.23 — StemSight Oy, the leading deep tech company dedicated to eliminating corneal blindness through stem cell technology, proudly announces the appointment of Dr Ross Macdonald to advance the Company’s commercial strategy. With over three decades of pharmaceutical and biopharma industry expertise, Macdonald’s inclusion in StemSight’s team brings a new breadth of experience to the Company. [Read more…]

How 3D Printing with Stem Cells will Alter the Future of Medicine

By Leave a Comment

Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more. Among its exciting and varied applications, combining 3D printing technologies with stem cells is one of the most exciting.

For this reason, this article explores critical advances in 3D printing and how this technology is creating positive opportunities for stem cell companies and investors.

[Read more…]

Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

By Leave a Comment

PALO ALTO, Calif., Nov. 1, 2023  — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. (“Heartseed”), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, have collaborated to generate cardiomyocytes using multiple donor-derived GMP grade iPS cell lines by I Peace, and Heartseed’s proprietary cardiomyocytes differentiation and purification methods. Heartseed has successfully produced high-purity cardiomyocytes consistently from all I Peace manufactured iPS cell lines used in this study. This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine with I Peace’s personal iPS cell banking service (My Peace), to manufacture and store iPS cells, and induce them into cardiomyocytes for use in autologous cell therapy. [Read more…]

Advanced Cell Models Usher in a New Era of Neuroscience Research

By 2 Comments

Neurodegenerative diseases, like Alzheimer’s and Parkinson’s disease are caused by progressive damage to cells of the nervous system. Patients suffering from these debilitating disorders lose their mobility, balance, speech, and so many other important functions. Scientists studying these disorders need advanced cell models that have the physiological and pharmacological properties seen in mature neurons. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0